Taiwan Showcases Biotech Innovations at BioJapan 2025

The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) from Taiwan has announced its leadership of a delegation comprising 16 biotech industry partners at BioJapan 2025, scheduled for October 8-10 in Yokohama, Japan. This initiative aims to highlight Taiwan’s robust biotech ecosystem and foster collaborations with Japanese companies in the fields of artificial intelligence (AI), regenerative medicine, and contract development and manufacturing (CDMO).

The Taiwan Pavilion will serve as a key platform for showcasing innovations in high-growth sectors such as regenerative medicine and precision health. BPIPO emphasizes Taiwan’s competitive edge and the potential benefits for Japanese firms in engaging with Taiwanese biotech capabilities.

Strengthening Taiwan-Japan Biotech Relations

Taiwanese firms have made significant inroads into the Japanese market. In 2024, Japan’s CBC became the official distributor for Taiwan’s Taipei Medical University Hospital (TBMC), marking a strategic expansion into Japan. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in the country, illustrating the growing acceptance of Taiwanese innovations.

This year, Amaran Biotech entered into a strategic partnership with Nippon Fine Chemical to advance CDMO manufacturing technology services for nanoparticle-based drugs, facilitating collaboration between the two nations. Notably, AM Biotech’s high-purity targeted exosomes have gained official registration with the Japan Cosmetic Industry Association, with applications extending from cosmetics to regenerative medicine.

Another highlight is LumiSTAR’s selection for Takeda Pharmaceutical’s COCKPI-T® program, aimed at enhancing drug discovery and development processes. Such partnerships underscore the increasing collaboration between Taiwan and Japan in the biotech sector.

Upcoming Collaborations and Innovations

The delegation will also witness the signing of a memorandum of understanding (MOU) between Creative Life Science and Japan’s Myoridge. This agreement aims to merge their strengths in cell culture and production, opening new avenues for regenerative medicine advancements.

Additionally, Steminent plans to achieve certification for its innovative regenerative medicine product, Stemchymal®, in 2026, following its recent acquisition of Foreign Manufacturer Accreditation from the Japanese government.

During their visit, the Taiwanese delegation will tour Astellas Pharma’s SakuLab facility, a leading Japanese multinational pharmaceutical company, to explore opportunities in cell therapy and bioprocessing. These interactions are expected to further solidify the ties between Taiwan’s biotech firms and their Japanese counterparts.

The complete list of the Taiwanese delegation is available on the BPIPO website. For media inquiries, please contact Janet Chung at [email protected].

As Taiwan continues to cultivate its biotech ecosystem, BioJapan 2025 presents an invaluable opportunity to showcase its innovations and strengthen international partnerships in biotechnology.